Marks, Jeffrey

Contact Information

Email:	mailto:jeffrey.marks@duke.edu
Fax:	(919) 681-6291

To update contact information, please visit the Data Management and Coordinating Center.

Open Protocols

Protocol Name	Biomarkers	Datasets
BBD Reference Set Application: Jeffery Marks-Duke (2015)	0	0
Benign Breast Disease Team Project	0	0
DCIS Team Project	0	0
Detection of Serum Markers of Breast Cancer by SELDI	0	0
Development of FISH-based assay for early detection of high grade cervical dysplasia	0	0
Early Detection of Breast Cancer Using Autoantibody Markers	0	0
Expression based markers for breast cancer detection	0	1
Identification of biomarkers for ER+ breast cancer	0	0
Standard Specimen Reference Set: Breast Cancer and Imaging	0	0
The Early Detection Research Network: Biomarker Reference Laboratories	0	0
Validation of Early Detection Ovarian Cancer Biomarkers (Team Project)	148	0

Closed Protocols

Protocol Name	Biomarkers	Datasets
Biomarker Detection Using NAPPA Tumor Antigen Arrays	1316	0
Breast Reference Set Application: Anu Mathew-Meso Scale (2012)	180	0
EDRN Resource Network Exchange	0	0
PTM Microarray: Request for Year 3 Set-Aside Funds	0	0
Triple Negative Breast Cancer Team Project	77	0
Year 2 Collaborative Project - UCSF and Battelle PNWD	0	0

Publications

Publication Name	PubMed ID	Journal
Acquired expression of periostin by human breast cancers promotes tumor angiogenesis through up-regulation of vascular endothelial growth factor receptor 2 expression.	15082792	Mol. Cell. Biol.
Analysis of methylation-sensitive transcriptome identifies GADD45a as a frequently methylated gene in breast cancer.	15735726	Oncogene
Development of an ovarian cancer screening decision model that incorporates disease heterogeneity: implications for potential mortality reduction.	21254049	Cancer
Do serum biomarkers really measure breast cancer?	19476629	BMC Cancer
Estrogen receptor alpha (ESR1) mutant A908G is not a common feature in benign and malignant proliferations of the breast.	15034868	Genes Chromosomes Cancer
Evaluation of expression based markers for the detection of breast cancer cells.	16319979	Breast Cancer Res. Treat.
Expression signatures of TP53 mutations in serous ovarian cancers.	20504346	BMC Cancer
Frequent IGF2/H19 domain epigenetic alterations and elevated IGF2 expression in epithelial ovarian cancer.	16603642	Mol. Cancer Res.
Glutamine synthetase is a genetic determinant of cell type-specific glutamine independence in breast epithelia.	21852960	PLoS Genet.
High throughput detection of M6P/IGF2R intronic hypermethylation and LOH in ovarian cancer.	16432260	Nucleic Acids Res.
Inactivation of the MAL gene in breast cancer is a common event that predicts benefit from adjuvant chemotherapy.	19208741	Mol. Cancer Res.
Isogenic normal basal and luminal mammary epithelial isolated by a novel method show a differential response to ionizing radiation.	17409405	Cancer Res.
Methylation patterns in cell-free plasma DNA reflect removal of the primary tumor and drug treatment of breast cancer patients.	20473856	Int. J. Cancer
Microarray analysis of early stage serous ovarian cancers shows profiles predictive of favorable outcome.	19318476	Clin. Cancer Res.
Novel tumor sampling strategies to enable microarray gene expression signatures in breast cancer: a study to determine feasibility and reproducibility in the context of clinical care.	19224362	Breast Cancer Res. Treat.
Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers.	15897565	Clin. Cancer Res.
Plasma biomarker profiles differ depending on breast cancer subtype but RANTES is consistently increased.	21586622	Cancer Epidemiol. Biomarkers Prev.
Pooling of case specimens to create standard serum sets for screening cancer biomarkers.	17301268	Cancer Epidemiol. Biomarkers Prev.
Progesterone receptor promoter +331A polymorphism is associated with a reduced risk of endometrioid and clear cell ovarian cancers.	15598772	Cancer Epidemiol. Biomarkers Prev.
Role of eotaxin-1 signaling in ovarian cancer.	19351767	Clin. Cancer Res.
Serum biomarker profiles and response to neoadjuvant chemotherapy for locally advanced breast cancer.	18474099	Breast Cancer Res.
TAFII70 isoform-specific growth suppression correlates with its ability to complex with the GADD45a protein.	15328371	Mol. Cancer Res.
The turnover of estrogen receptor α by the selective estrogen receptor degrader (SERD) fulvestrant is a saturable process that is not required for antagonist efficacy.	21501600	Biochem. Pharmacol.
The type III TGF-beta receptor suppresses breast cancer progression.	17160136	J. Clin. Invest.
Validation of ovarian cancer gene expression signatures for survival and subtype in formalin fixed paraffin embedded tissues.	23274563	Gynecol. Oncol.
Yeast screens identify the RNA polymerase II CTD and SPT5 as relevant targets of BRCA1 interaction.	18197258	PLoS ONE

To update protocols, publications, biomarkers, or science data, please contact the Informatics Center.